Online inquiry

IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15815MR)

This product GTTS-WQ15815MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD3E&IL3RA gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_000733.4; NM_001267713.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 3563
UniProt ID P07766; P26951
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ15815MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2672MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 655
GTTS-WQ484MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ12863MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OPN-305
GTTS-WQ2896MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG827
GTTS-WQ10561MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY­3074828
GTTS-WQ5585MR IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP7766
GTTS-WQ12567MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NV-02
GTTS-WQ12062MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MOR-00208
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW